PROCEPT BioRobotics Corporation announced on July 23, 2025, that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC). Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona, performed these procedures using Aquablation therapy.
This achievement marks a major milestone for the company, demonstrating that early-stage prostate cancer can be safely treated at an ASC with Aquablation therapy. Patients undergoing these procedures were discharged the same day without complications, indicating a safe prostate resection and efficient care model.
The successful completion of these procedures in an ASC highlights the potential for a more scalable and cost-effective care model in the rapidly changing market for prostate cancer treatment. The WATER IV PCa trial is an FDA investigational device exemption (IDE) approved clinical study comparing Aquablation therapy to radical prostatectomy for localized prostate cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.